Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-27623
Dedes, K J; Matter-Walstra, K; Schwenkglenks, M; Pestalozzi, B C; Fink, D; Brauchli, P; Szucs, T D (2009). Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. European Journal of Cancer, 45(8):1397-1406.
- Registered users only
The addition of bevacizumab to weekly paclitaxel as primary chemotherapy for HER-2 negative metastatic breast cancer (MBC) prolongs progression-free survival without a substantial increase of toxicity. A Markov cohort simulation was used to follow the clinical course of typical patients with MBC. Information on response rates and major adverse effects was derived, and transition probabilities were estimated, based on the results of the E2100 clinical trial. Direct costs were assessed from the perspective of the Swiss health system. The addition of bevacizumab to weekly paclitaxel is estimated to cost an additional 40,369euro and to yield a gain of 0.22 quality-adjusted life years (QALYs), resulting in an incremental cost-effectiveness ratio of 189,427euro/QALY gained. Probabilistic sensitivity analysis showed that the willingness-to-pay threshold of 60,000euro was never reached. The addition of bevacizumab to paclitaxel in MBC patients is expensive given the clinical benefit in terms of QALYs gained.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > Institute of Social and Preventive Medicine|
04 Faculty of Medicine > University Hospital Zurich > Clinic for Gynecology
|DDC:||610 Medicine & health|
|Deposited On:||15 Jan 2010 12:37|
|Last Modified:||28 Nov 2013 02:13|
|Citations:||Web of Science®. Times Cited: 35|
Scopus®. Citation Count: 43
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page